Given Omicron Varinat’s potential higher rate of transmissibility, Fapon Biotech has successfully introduced SARS-CoV-2 Omicron Variant Neutralizing Antibody Titer Testing Solution (ELISA) to effectively evaluate the immune evasiveness and vaccine effectiveness on Omicron varian.
Depixus raises €30.6m in Series A financing
Latest NewsFrench-British magnetic trap specialist Depixus has raised €30,6m to develop a commercial instrument based on the company’s MAGNA technology.
Ichnos Sciences in licence deal with Almirall
Latest NewsIchnos Sciences Inc. has licenced the gobal rights on its IL-1RAP antagonistic antibody ISB 880 to Almirall SA for the treatment of autoimmune disorders.
Vifor Pharma Ltd to be acquired for CHF10.9bn
Latest NewsBiologicals and vaccine specialist CSL Ltd is set to acquire Swiss Vifor Pharma Ltd for CHF10.9bn.
Fapon Biotech Races to Introduce Omicron Neutralizing Antibodies Titer Testing Solution
ProductsGiven Omicron Varinat’s potential higher rate of transmissibility, Fapon Biotech has successfully introduced SARS-CoV-2 Omicron Variant Neutralizing Antibody Titer Testing Solution (ELISA) to effectively evaluate the immune evasiveness and vaccine effectiveness on Omicron varian.
Successor wanted
AppointmentsGabriella Björknert Caracciolo will leave Bactiguard AB, where she currently works as CFO and deputy CEO.
Apogenix gets €25.8m cash injection for asunercept
Latest NewsGerman Apogenix AG has received a €26m in funding for a pivotal Phase III study of its CD95 ligand blocker asunercept for the treatment of COVID-19 patients.
British Adendra Therapeutics closes $53m financing
Latest NewsThe 2021 spin out of London-based Francis Crick Institute is the very first UK company formation deal of life sciences investor ATP (Apple Tree Partners).
Back as CEO
AppointmentsSwedish Oncopeptides has had a new CEO since mid-November. Jakob Lindberg has taken over the position from Marty J. Duvall again. He has left the company.
Accelerating biologics development
Sponsored PublicationsAbstract: This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly. Criteria includes:
Accelerating biologics development
Sponsored PublicationsAbstract: This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly. Criteria includes: